ReviewCancers2022
Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 66 citations in OpenAlex.
- Carbon-Ion Radiation Therapy for Unresectable Solitary Fibrous Tumor of the Intermediate Category: A Nationwide Multi-institutional Observational Study by the Japan Carbon-Ion Radiation Oncology Study Group.Advances in radiation oncology · 2026Article
- The Silent Intruder: A Case Report of an Incidentally Discovered Solitary Fibrous Tumor of the Lung.Cureus · 2026Article
- How I treat soft tissue sarcomas.Future oncology (London, England) · 2026Review
- Systemic Therapy for Solitary Fibrous Tumor.Current treatment options in oncology · 2026Review
- Advances in the multimodal management of central nervous system solitary fibrous tumors.Frontiers in oncology · 2026Review
- Solitary Fibrous Tumor With a 12-Year Recurrence Interval in a Female Patient: A Case Report.Cureus · 2026Article
- Solitary fibrous tumor of the lung: diagnostic challenges and surgical management.Exploration of targeted anti-tumor therapy · 2026Article
- Solitary fibrous tumor: an updated review.Journal of pathology and translational medicine · 2026Article
- Solitary Fibrous Tumor Generated From Uterine Corpus With Doege-Potter Syndrome in Primary Disease: A Rare Case of Recurrent Disease Without Hypoglycemia.Case reports in obstetrics and gynecology · 2026Article
- A Case of Solitary Fibrous Tumor with Tumor Rupture during the Waiting Period for Elective Surgery.Surgical case reports · 2026Article
- Pelvic solitary fibrous tumors: clinical manifestations, surgical management and long-term outcomes.Frontiers in oncology · 2026Article
- Primary orbital solitary fibrous tumor with an 18-year course of five recurrences and extensive sinonasal metastasis following eyeball enucleation: a case report.Frontiers in medicine · 2026Article
- Solitary Fibrous Tumors of the Pleura With Extensive Intrathoracic Occupation: Report of Two Cases.Case reports in pulmonology · 2026Article
- Solitary Fibrous Tumor of the Forehead.Indian dermatology online journal · 2025Article
- Article
- Solitary fibrous tumors from A to Z: a pictorial review with radiologic-pathologic correlation.Insights into imaging · 2025Article
- Adverse Outcome of a Solitary Fibrous Tumor Originating in the Bladder.IJU case reports · 2025Article
- Low-grade intracranial solitary fibrous tumor with early metastasis to lumbar spine and recurrence twice: case report.Discover oncology · 2025Article
- Establishment and characterization of NCC-SFT1-C1: a novel patient-derived cell line of solitary fibrous tumor.Human cell · 2025Article
- Imaging assessment of tumor densities and sizes following pazopanib treatment for central nervous system solitary fibrous tumors with multiple extracranial metastases: A case series.Oncology letters · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SFT is an ultrarare mesenchymal ubiquitous tumor, with an incidence rate <1 case/million people/year. The fifth WHO classification published in April 2020 subdivided SFT into three categories: benign (locally aggressive), NOS (rarely metastasizing), and malignant. Recurrence can occur in up to 10-40% of localized SFTs, and several risk stratification models have been proposed to predict the individual risk of metastatic relapse. The Demicco model is the most widely used and is based on age at presentation, tumor size, and mitotic count. Total en bloc resection is the standard treatment of patients with a localized SFT; in case of advanced disease, the clinical efficacy of conventional chemotherapy remains poor. In this review, we discuss new insights into the biology and the treatment of patients with SFT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.